Vitiligo - Epidemiology Forecast to 2027 - ResearchAndMarkets.com

October 8, 2018

DUBLIN--(BUSINESS WIRE)--Oct 8, 2018--The “Vitiligo - Epidemiology Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Vitiligo in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Study Period: 2016-2027

Vitiligo Epidemiology

The Vitiligo epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Vitiligo are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Vitiligo Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Prevalent population, Sex specific cases, Diagnosed Cases, Type Specific Diagnosed cases (segmental, non-segmental and unclassified) and Age Specific cases] scenario of Vitiligo in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According this research, the total prevalent population of Vitiligo was found to be 6,136,840 in the year 2016.

Report Scope

The report covers detailed overview of Vitiligo explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns The report provides the insight about the historical and forecasted patient pool of Vitiligo in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan The report assesses the disease risk and burden and highlights the unmet needs of the disease The report helps to recognize the growth opportunities in the 7MM with respect to the patient population The report provides the segmentation of the disease epidemiology by type i.e., Non-segmental, segmental and unclassified vitiligo, age and sex specific cases in 7MM

Key Strengths

10 Year Forecast of Vitiligo 7MM Coverage Total Prevalent Cases of Vitiligo Prevalent Cases according to segmentation: Sex Specific cases, Type Specific Diagnosed Prevalent cases and Age Specific cases of Vitiligo

Key Assessments

Patient Segmentation Disease Risk & Burden Risk of disease by the segmentation Factors driving growth in a specific patient population

For more information about this report visit https://www.researchandmarkets.com/research/rpcmqd/vitiligo?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181008005353/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Dermatological Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 10/08/2018 07:19 AM/DISC: 10/08/2018 07:19 AM


Update hourly